STAGE IV NON-SMALL CELL LUNG CANCER
Clinical trials for STAGE IV NON-SMALL CELL LUNG CANCER explained in plain language.
Never miss a new study
Get alerted when new STAGE IV NON-SMALL CELL LUNG CANCER trials appear
Sign up with your email to follow new studies for STAGE IV NON-SMALL CELL LUNG CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy shows promise against tough cancers
Disease control CompletedThis study tested a combination of two drugs—sEphB4-HSA and pembrolizumab—in 42 people with advanced non-small cell lung cancer or head & neck cancer that had spread or returned. The goal was to see if the combo could shrink tumors better than standard treatments. Participants ha…
Matched conditions: STAGE IV NON-SMALL CELL LUNG CANCER
Phase: PHASE2 • Sponsor: University of Southern California • Aim: Disease control
Last updated Jun 15, 2026 19:08 UTC
-
Radiation boosts immunotherapy in advanced lung cancer trial
Disease control CompletedThis study tested whether adding high-dose, precisely targeted radiation to standard immunotherapy can help control stage IV non-small cell lung cancer. Forty-five adults who were already on immunotherapy received radiation to some tumors. The main goal was to see how many patien…
Matched conditions: STAGE IV NON-SMALL CELL LUNG CANCER
Phase: NA • Sponsor: Stanford University • Aim: Disease control
Last updated Jun 15, 2026 18:55 UTC
-
New combo therapy shows promise for brain metastases
Disease control CompletedThis early study tested combining the immunotherapy drug pembrolizumab with precise radiation (stereotactic radiosurgery) in 25 people with melanoma or lung cancer that had spread to the brain. The main goal was to check for serious side effects. Researchers also tracked how long…
Matched conditions: STAGE IV NON-SMALL CELL LUNG CANCER
Phase: PHASE1 • Sponsor: Emory University • Aim: Disease control
Last updated Jun 15, 2026 18:55 UTC
-
New drug combo shows promise in early lung cancer trial
Disease control CompletedThis early-phase study tested a new drug called ONO-7475 combined with the standard targeted therapy osimertinib in 78 people with advanced EGFR-mutated non-small cell lung cancer. The main goal was to check safety and find the right dose. Researchers also looked at how well the …
Matched conditions: STAGE IV NON-SMALL CELL LUNG CANCER
Phase: PHASE1 • Sponsor: Ono Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 12, 2026 12:07 UTC
-
New drug combo shows promise for tough lung cancers
Disease control CompletedThis study tested a combination of two drugs, auranofin and sirolimus, in 29 people with advanced or recurrent lung cancer who had run out of standard treatment options. The goal was to find the best dose and see if the combo could slow or stop cancer growth. The trial focused on…
Matched conditions: STAGE IV NON-SMALL CELL LUNG CANCER
Phase: PHASE1, PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 11, 2026 12:09 UTC
-
New combo therapy shows promise for hard-to-treat lung cancer
Disease control CompletedThis study tested a combination of a cancer vaccine (TG4010) and an immunotherapy drug (nivolumab) in 13 people with advanced non-small cell lung cancer who had already received other treatments. The goal was to see if the combination could shrink tumors or stop them from growing…
Matched conditions: STAGE IV NON-SMALL CELL LUNG CANCER
Phase: PHASE2 • Sponsor: Megan Daly, MD • Aim: Disease control
Last updated Jun 08, 2026 13:11 UTC
-
Double-Drug attack on lung cancer: does adding cetuximab help?
Disease control CompletedThis study looked at whether adding cetuximab to the standard drug afatinib works better than afatinib alone for people with advanced or recurrent EGFR-mutant non-small cell lung cancer. 174 newly diagnosed patients were randomly assigned to one of the two treatments. The goal wa…
Matched conditions: STAGE IV NON-SMALL CELL LUNG CANCER
Phase: PHASE2, PHASE3 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated Jun 03, 2026 12:03 UTC
-
New radiation approach targets multiple tumors at once in early safety trial
Symptom relief CompletedThis early-phase study tested a high-precision radiation technique called stereotactic body radiotherapy (SBRT) in 42 adults with breast, lung, or prostate cancer that had spread to several spots in the body. The main goal was to find the safest dose and check for side effects wh…
Matched conditions: STAGE IV NON-SMALL CELL LUNG CANCER
Phase: PHASE1 • Sponsor: NRG Oncology • Aim: Symptom relief
Last updated Jun 09, 2026 12:09 UTC